Myrtle Potter

Sumitovant Biopharma, Inc

Myrtle Potter is a global healthcare innovator and the CEO of Sumitovant Biopharma, a technology-driven, patient-first biopharmaceutical company with a diverse portfolio of commercialized therapies and a pipeline of early- to late-stage assets.  Previously, Myrtle served as Vant Operating Chair of Roivant Sciences where she oversaw nine biopharmaceutical companies with more than 30 investigational drugs in 11 therapeutic areas and guided two of the companies through successful IPOs. Prior to Roivant, she served as CEO of Myrtle Potter & Company, a healthcare advisory firm she founded in 2005. Potter

HLTH does not sell or provide any personal data (including email, phone, address) to any third parties and we never will. Any communication that pretends to be HLTH or any third parties selling purported lists, discounted rooms, or any product/services are NOT AFFILIATED with HLTH and are to be considered FRAUD.

Upcoming Event Dates

2024 | ViVE: Feb 25-28; HLTH Europe: Jun 17-20; HLTH US: Oct 20-23

2025 | ViVE: Feb 16-19; HLTH US: Oct 19-22

2026 | HLTH US: Nov 15-18

2027 | HLTH US: Oct 17-20

© 2024 HLTH, INC. All Rights Reserved